Paula D. Riggs, M.D., Receives AACAP Elaine Schlosser Lewis Award for Research on Attention-Deficit Disorder
Reports award-winning article in Journal of the American Academy of Child and Adolescent Psychiatry
Washington D.C., October 29, 2012 – The American Academy of Child and Adolescent Psychiatry (AACAP) is pleased to announce Paula D. Riggs, M.D., Director, Division of Substance Dependence, University of Colorado–Denver, as the AACAP Elaine Schlosser Lewis Award for Research on Attention-Deficit Disorder recipient for her paper, "Randomized Controlled Trial of Osmotic-Release Methylphenidate With Cognitive-Behavioral Therapy in Adolescents With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders," published in the September 2011 issue of the Journal of the American Academy of Child and Adolescent Psychiatry and online at www.jaacap.org.1
The AACAP Elaine Schlosser Lewis Award for Research on Attention-Deficit Disorder was established through support of the Elaine Schlosser Lewis Fund in 1994. The award of $5,000 is given annually for the best paper published in the Journal of the American Academy of Child and Adolescent Psychiatry on attention-deficit disorder, written by a child and adolescent psychiatrist, and published between July 2010 and June 2011. This award is named in memory of Dr. Owen Lewis's late mother, Elaine Schlosser Lewis, who was a teacher and advocate on behalf of children.
The researchers compared osmotic-release methylphenidate (OROS-MPH) and placebo in 303 participants, aged 13-18, who met DSM-IV criteria for ADHD and substance abuse disorder (SUD), and who were concurrently receiving cognitive-behavioral therapy (CBT) for SUD. The study found that OROS-MPH was not more effective than placebo for ADHD or on reduction in substance use among the adolescents, but was associated with modest clinical improvement on secondary ADHD and substance treatment outcomes, such as problem-solving and managing drug/alcohol temptations.
The researchers address questions such as the reliability of the assessments and of using multiple informants, the adolescents’ medication compliance, and whether or not the efficacy of OROS-MPH was compromised by the participants’ use of drugs/alcohol. The authors highlight the need for future studies to address the effect of CBT for SUD in the context of ADHD, and to determine the most effective methods of evaluating ADHD treatment outcomes and of assessing adolescents with co-occuring disorders.
Dr. Riggs presented "Randomized Controlled Trial of Osmotic-Release Methylphenidate With Cognitive-Behavioral Therapy in Adolescents With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders," at AACAP's 59th Annual Meeting, October 26, 2012, in San Francisco.
1. Riggs PD, Winhusen T, Davies RD et al. Quality of Care for Childhood Attention-Deficit/Hyperactivity Disorder in a Managed Care Medicaid Program. J. Am. Acad. Child Adolesc. Psychiatry, 2011; 50(9): 903-914.
# # #
Full text of the article is available to credentialed journalists upon request; contact Mary Billingsley at +1 202 966 7300 x105 or firstname.lastname@example.org. Journalists wishing to interview the authors may contact Dr. Riggs at email@example.com.
All articles published in JAACAP are embargoed until 3PM ET of the day they are published as corrected proofs online. Articles cannot be publicized as accepted abstracts. Contents of the publication should not be released to or by the media or government agencies before this date.
American Academy of Child and Adolescent Psychiatry (AACAP)
Representing over 8,000 child and adolescent psychiatrists nationwide, AACAP is the leading national professional medical association dedicated to treating and improving the quality of life for children, adolescents, and families affected by mental, behavioral, and developmental disorders.
Journal of the American Academy of Child & Adolescent Psychiatry is the flagship journal of the American Academy of Child and Adolescent Psychiatry and is the leading journal focusing exclusively on today's psychiatric research and treatment of the child and adolescent. Published twelve times per year, each issue is committed to its mission of advancing the science of pediatric mental health and promoting the care of youth and their families.
JAACAP’s goal is to advance the science of child and adolescent psychiatry by publishing original research and papers of theoretical, scientific, and clinical relevance to the field. JAACAP welcomes unpublished manuscripts whose primary focus is on the mental health of children, adolescents, and families. Submissions may come from diverse viewpoints including but not limited to: genetic, epidemiological, neurobiological, and psychopathological research; cognitive, behavioral, psychodynamic, and other psychotherapeutic investigations; parent-child, interpersonal, and family research; and, clinical and empirical research in inpatient, outpatient, consultation-liaison, and school-based settings. JAACAP also seeks to promote the well-being of children and families by publishing scholarly papers on such subjects as health policy, legislation, advocacy, culture and society, and service provision as they pertain to the mental health of children and families.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
JAACAP Editorial Office
+1 202 966 7300 x105